ACTRN12617001381370已完成1 期
A Phase I, Three-Period, Three-Way, Randomized, Open-Label, Single-Dose, Cross-Over, Comparative Bioavailability Study of Dihydroergotamine Mesylate (DHE) Administered by I123 Precision Olfactory Delivery (PODTM) Device Nasal Spray, DHE for Injection (Intravenous), and Migranal® Nasal Spray in Healthy Adult Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
A multiple dose study of ZYN002 (transdermal gel) in Healthy Volunteers and Patients with EpilepsyEpilepsyACTRN12616000104459Zynerba Pharmaceuticals Inc.36
进行中（未招募）
不适用
Trial to study the pharmacokinetics and food effect of solid and liquid formulations of TMC435 versus the referenceHepatitis C Virus (HCV) genotype-1 InfectionMedDRA version: 14.1Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-005808-14-GBJanssen R&D Ireland
进行中（未招募）
不适用
A phase III, open, randomized, controlled, primary vaccination study to demonstrate non-inferiority of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY conjugate vaccine compared to licensed MenC-CRM197 conjugate vaccine when administered to healthy subjects aged 2 through 10 years. - MenACWY-TT-081 PRIEUCTR2007-007837-38-DEGlaxoSmithKline Biologicals400
进行中（未招募）
1 期
A phase III, open, randomized, controlled, primary vaccination study to demonstrate non-inferiority of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY conjugate vaccine compared to licensed MenC-CRM197 conjugate vaccine when administered to healthy subjects aged 2 through 10 years. - MenACWY-TT-081 PRIEUCTR2007-007837-38-FRGlaxoSmithKline Biologicals414
已完成
不适用
A three-part, phase 1, randomized, controlled, dose-escalation study of INT-787 following single or multiple dose administration in healthy subjects.NL-OMON52038Intercept Pharmaceuticals, Inc.96